Trials / Completed
CompletedNCT00322283
Study of Oglemilast for the Prevention of Asthma.
Efficacy and Safety of Oglemilast in the Prevention of Exercise-Induced Bronchospasm
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether it is effective in the treatment of exercise-induced asthma and investigate the safety of oglemilast.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oglemilast | Oglemilast, 15mg once per day, oral administration |
| DRUG | Placebo | Dose-marched placebo, once per day, oral administration |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2006-10-01
- Completion
- 2006-10-01
- First posted
- 2006-05-05
- Last updated
- 2012-04-10
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00322283. Inclusion in this directory is not an endorsement.